Did you mean: 9826 FRCA, LLC v. Hurwitz et al?
Web Results

9826 LFRCA, LLC v. Hurwitz et al, No. 3:2013cv01042 - Document ...

law.justia.com/cases/federal/district-courts/california/casdce/3:2013cv01042/413501/23/

9826 LFRCA, LLC v. Hurwitz et al, No. 3:2013cv01042 - Document 23 (S.D. Cal. 2014) case opinion from the Southern District of California U.S. Federal District ...

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for ... - NCBI

www.ncbi.nlm.nih.gov/pubmed/15175435

Jun 3, 2004 ... Hurwitz H(1), Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, ... with IFL plus bevacizumab than with IFL plus placebo (11.0 percent vs.

Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3780632/

Jul 23, 2013 ... Herbert I. Hurwitz, <sup>corresponding author</sup> ... variables by treatment (chemotherapy with or without placebo vs. chemotherapy plus bevacizumab), stratified .... The fixed-effects model was based on methodology by Parmar et al.

More Info

Bevacizumab in combination with fluorouracil and leucovorin: an ...

www.ncbi.nlm.nih.gov

May 20, 2005 ... Hurwitz HI(1), Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Author information:

Effect of bevacizumab in older patients with metastatic colorectal ...

www.ncbi.nlm.nih.gov

Nov 11, 2009 ... 2008)] and one second-line [E3200 (Giantonio et al. ... to the 5-FU/LV plus bevacizumab arm was halted after an interim analysis (Hurwitz et al. .... cause appeared to be lower in bevacizumab-treated patients (<65 years 69 vs.

Should FOLFOXIRI Plus Bevacizumab Be the Standard First-Line ...

www.ncbi.nlm.nih.gov

Feb 6, 2015 ... Notably, secondary complete (R0) liver resection rates (15% vs. 12%) did not .... Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab ...